

# *CURRICULUM VITAE*

Joseph M. Coney, MD

**OFFICE ADDRESSES** Retina Associates of Cleveland, Inc.  
3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122  
14601 Detroit Avenue, Suite 200; Cleveland, Ohio 44107  
15299 East Bagley Road, Suite 200; Cleveland, Ohio 44130  
5390 Belmont Avenue; Youngstown, Ohio 44505  
1 Park West, Suite 150; Akron, Ohio 44320  
3919 East Market Street; Warren, Ohio 44484  
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060  
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052

**TELEPHONE** 216-831-5700

## **EDUCATION**

*College* University of Illinois  
Champaign, Illinois  
1990-1994, BS (Biology)

*Medical School* Loyola-Stritch School of Medicine  
Maywood, Illinois  
1995-1999, MD

## **POSTGRADUATE TRAINING**

*Internship* Transitional  
Resurrection Medical Center  
Chicago, Illinois  
1999-2000

*Residency* Ophthalmology  
Case Western Reserve University  
Cleveland, Ohio  
2000-2003

*Fellowship* Medical Retina Fellowship  
Joslin Diabetes Center- an affiliate of Harvard Medical School  
Boston, Massachusetts  
2003-2004

Surgical Retina Fellowship (2 years)  
Vitreoretinal Foundation  
Memphis, Tennessee  
2004-2006

## LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio, Pennsylvania, Tennessee, Arkansas, and Mississippi

Diplomate, American Board of Ophthalmology, 2006

## PROFESSIONAL POSITIONS

*Retina Associates of Cleveland*, 2006-

Private practice in vitreoretinal surgery and diseases. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; David G. Miller, MD; Jerome P. Schartman, MD

*Diabetes Association of Greater Cleveland*

Board of Directors, 2006-

*Cleveland Ophthalmological Society*

Secretary, 2011-

*Eyetech Inc.*

Clinical Advisory Board, 2008-2010

*Allergan*

Clinical Advisory Board, 2010

*American Academy of Ophthalmology*

Selected participant, Leadership Development Program, 2007-2008

## ACADEMIC APPOINTMENTS

Senior Clinical Instructor, Department of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine/University Hospitals of Cleveland, Cleveland, Ohio, November 2008-

## OTHER ACADEMIC AND ADMINISTRATIVE POSITIONS

*Resident Mentor*, 2003-2004

Massachusetts General Hospital

*Mentor Coordinator, 1996*

Robert Wood-Johnson Foundation, Minority Medical Education Program

*Inter-Fraternal Greek Council, 1993-1995*

Board of Fraternity Affairs, University of Illinois at Urbana-Champaign

*Chapter President (Polmarch), 1992-1994*

Kappa Alpha Psi Fraternity, University of Illinois at Urbana-Champaign

*Minority Organization for Pre-Health Students, 1992-1994*

University of Illinois at Urbana-Champaign

Chapter President, 1993-1994

Chapter Treasurer, 1992-1993

## PROFESSIONAL SOCIETIES AND COMMITTEES

*American Eye Study Club, 2010-*

*American Society of Retinal Specialists, 2007-*

*Roman-Barns Society of Ophthalmology, 2007*

*National Medical Association*

Postgraduate section liaison, 2005-

Board of Directors - Ophthalmology Section, 2005-

Secretary - Ophthalmology Section, 2005-

Chair - Retina Section, 2009-

Councilor to the American Academy of Ophthalmology Council, 2009-

*Ohio State Medical Association, 2007-*

*Academy of Medicine of Cleveland and Northern Ohio, 2007-*

*Diabetes Association of Greater Cleveland, 2007-*

Professional Member

*Cleveland Ophthalmologic Society, 2000-2003, 2006-*

Secretary, 2011-

*Endocrine Society, 2002-*

*United States Boxing Federation Fight Doctor, 2001-*

*American Academy of Ophthalmology, 2000-*

*Cook County Physicians Association, 1996-2001*

*American Medical Association, 1996-1999*

*Student National Medical Association, 1995-1999*

Chairman of National Convention, 1997-1998

Member Board of Directors, 1997-1998

Local Chapter President, 1997-1998

Local Chapter, Treasurer 1995-1996

National Delegate, 1995-1999

Region II Delegate, 1995, 1996, 1999

Region II Fundraiser Coordinator, 1996-1997

*Medical Student Union Representative, 1995-1999*

Loyola-Stritch School of Medicine

*Primary Care Committee Chair, 1995*

American Medical Student Association

*University of Illinois Alumni Association, 1995-*

*Kappa Alpha Psi Fraternity Inc., 1992-*

## HONORS AND AWARDS

America's Top Ophthalmologists, Consumers Research Council of America, 2007

Cambridge Who's Who of Executives and Professionals, Honored Life Time Member, 2007

Service Award, 2006

National Medical Association; Dallas, Texas

Rabb-Venable Award for Outstanding Fellow Research Presentation, 2004

National Medical Association; San Diego, California

Rabb-Venable Award for Outstanding Resident Research Presentation, 2003

National Medical Association; Philadelphia, Pennsylvania

Outstanding Resident Research Award, 2003

Case Western Reserve University; Cleveland, Ohio

Janice Douglas - David Satcher Clerkship, 1999

Case Western Reserve University; Cleveland, Ohio

National Merit Award, 1995

Student National Medical Association

Member of the Year, 1995

Student National Medical Association

Cook County Physicians Association Scholarship Recipient, 1995  
Chicago, Illinois

Dean's List, College of Liberal Arts & Science, 1990-1993  
University of Illinois; Champaign, Illinois

Delta Sigma Theta Scholarship Recipient, 1991

Alpha Lambda Delta National Honor Society, 1990  
University of Illinois; Champaign, Illinois

Phi Eta Sigma Freshman Honor Society, 1990  
University of Illinois, Champaign, Illinois

## HOSPITAL AFFILIATIONS

Akron City Hospital, Akron, Ohio  
Akron General Medical Center, Akron, Ohio  
Austintown Surgery Center, Youngstown, Ohio  
Chagrin Surgery Center, Beachwood, Ohio  
Hillcrest Hospital, Mayfield Heights, Ohio  
Jameson Hospital, New Castle, Pa  
Lake West Hospital, Willoughby, Ohio  
Lakewood Hospital, Lakewood, Ohio  
Parma Community General Hospital, Parma, Ohio  
Southwest General Health Center, Middleburg Heights, Ohio  
St. Elizabeth Medical Center, Youngstown, Ohio

## RESEARCH ACTIVITIES

### *NIH-funded Grants*

*DRCRnet Protocol N. Evaluation of intravitreal ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy.*

Co-investigator, 2010-

*DRCRnet Protocol O. Comparison of time-domain OCT and spectral domain OCT retinal thickness measurement in diabetic macular edema*

Co-investigator, 2009-2010

*Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial (CATT)*

Co-investigator, 2008-

*DRCRnet Protocol I. Intravitreal ranibizumab or triamcinolone acetonide in combination with laser photocoagulation for diabetic macular edema (Diabetic Retinopathy Clinical*

Research Network /NIH)  
Co-investigator, 2007-

*DRCRnet Protocol K. Course of response to focal photocoagulation for diabetic macular edema*  
Co-investigator, 2007-2008

*Age-Related Eye Disease Study (AREDS) 2*  
Co-investigator, 2006-

*Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study*  
Co-investigator, 2006-2009

### ***Other National Clinical Trials***

*A 2 year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN211745 (small interfering RNA) in subjects with subfoveal CNV secondary to AMD (SIRIUS)*  
Principal investigator, 2006-2008

*Multi-center, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of voclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-uveitis*  
Co-investigator, 2011-

*Phase 2b dose-ranging study of pazopanib eye drops versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration*  
Co-investigator, 2010-

*Phase II, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with lucentis in subjects with neovascular age related macular edema (Ophthotech 1001)*  
Co-investigator, 2010-

*Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion*  
Co-investigator, 2009-

*Phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR) (Genentech)*  
Co-investigator, 2009-

*Geographic Atrophy Treatment Evaluation (GATE) Study*  
Co-investigator, 2009-

*Phase Ia, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of FCFD4514S in patients with geographic atrophy*

Co-investigator, 2009-2010

*Phase II, randomized, double-masked, placebo- controlled, add-on study to assess the efficacy of oral aliskiren 300 mg one daily for diabetic macular edema*

Co-investigator, 2009-2010

*Natural History of Geographic Atrophy Progression (GAP) Study*

Co-investigator, 2008-2009

*Phase I, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ( $\alpha 5\beta 1$  integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)*

Co-investigator, 2008-

*Randomized, placebo controlled, double-masked, multicenter trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion*

Co-investigator, 2008-2010

*Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with DME secondary to diabetic retinopathy*

Co-investigator, 2008-2010

*Phase I, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD (Ophthotech 1000)*

Co-investigator, 2007-2008

*A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin for Vitreous Injection III) Trial*

Co-investigator, 2007-2008

*A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700  $\mu$ g dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema*

Co-investigator, 2007-2010

*A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)*

Co-investigator, 2007-

*COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)*

Co-investigator, 2007-2008

*Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)*

Co-investigator, 2007-2009

*OMEGA: a randomized, double-masked, dose-ranging, multi-center, Phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration*

Co-investigator, 2007-2009

*Denali: a 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne® photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration*

Co-investigator, 2007

*Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC): Comparison of PHP (Preferential Hyperacuity Perimetry) with supervised Amsler grid in detecting neovascular AMD in eyes at high risk for CNV*

Co-investigator, 2007-2009

*Sirion Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration*

Co-investigator, 2007-2010

*A 3-year, Phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema*

Co-investigator, 2006-2007

*Eyetech 1023: Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement*

Co-investigator, 2006-2008

*Protein Kinase C  $\beta$  Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema*

Co-investigator, 2006-2010

*Protein Kinase C  $\beta$  Inhibitor Study B7A-MC-MBCU. Effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography*

Co-investigator, 2006-

*A Phase IIIb, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization secondary to age-related macular degeneration (SAILOR)*

Co-investigator, 2006-2007

*A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration*

Co-investigator, Memphis (Tennessee) Center, 2005-2006

### **Other Research Activities**

*Evaluation of hydroxychloroquine retinopathy with multifocal electroretinogram*

Co-investigator, Joslin Diabetes Center, Boston MA, 2003-2004

*Evaluation of patients with fifty or more years of insulin dependent diabetes mellitus*

Co-investigator, Joslin Diabetes Center, Boston MA, 2003-2004

*Study of genes and enzymes responsible for diabetic retinopathy*

Co-investigator, Joslin Diabetes Center, Boston MA, 2003

*Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study*

Co-investigator Retina Associates of Cleveland, 2002

*Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study*

Co-investigator, University Hospitals of Cleveland-CWRU, 2001

*Treatment of serous retinal detachments in optic nerve head pits with periocular steroids and carbonic anhydrase inhibitors: case studies*

Co-investigator, Retina Associates of Cleveland, 2001

*Measurement of corneal thickness changes after prolonged swimming with goggles*

Medical student, Loyola Medical Center; Department of Ophthalmology,  
Maywood IL, 1998

*I-CAM expression on bone marrow stromal cells*

Research assistant, Loyola-Stritch School of Medicine; Department of Burn-Shock & Trauma Institute, Maywood IL, 1996

Abbott Laboratories; Department of Research & Development, North Chicago IL  
Research Assistant, 1995

United States Construction Engineering Research Laboratory, Champaign IL  
Environmental Research Assistant, 01/94-12/94

The Dow Chemical Company; Department of Analytical Section, Midland MI  
Analytical Science Intern in X-Ray Fluorescence, 05/94-08/94

## SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA

Emerging treatments for diabetic retinopathy

- Optometric Retinal Update; Beachwood, Ohio  
March 3, 2011

Retina Moderator, National Medical Association Annual Convention and Scientific Assembly; Orlando, Florida  
August 1, 2010

Brown CC, Coney JM, H. Zegarra H. Results of photodynamic therapy with verteporfin for the treatment of central serous chorioretinopathy.

- Rabb Venable Research Competition..  
August 1, 2010

Update on diabetic retinopathy

- Optometric Retinal Update; New Castle, Pennsylvania  
May 13, 2010

Singerman LJ, Novak MA, Miller DG, Coney JM, et al. Ranibizumab treatment for pigment epithelial detachment (PED) in age-related macular degeneration (AMD).

- Retina Congress 2009, Combined Meeting of the American Society of Retina Specialists, The Macula Society, and The Retina Society; New York, New York  
September 30-October 4, 2009

Neovascular peripheral retinal disease

- Optometric Retinal Update; Youngstown, Ohio  
August 20, 2009

Retina surgery videos (with David G. Miller, MD)

- National Medical Association Annual Meeting; Las Vegas, Nevada  
July 25-29, 2009

Berlon NR, Miller DG, Novak MA, Pendergast SD, Coney JC. Safety and efficacy of 25-gauge vitrectomy surgery by experienced vitreoretinal surgeons.

- Association for Research in Vision and Ophthalmology Annual Meeting. Program # 5202; Fort Lauderdale, Florida.  
May 7, 2009.

Diabetes and the eye

- Cleveland Ophthalmic Personnel Society; Independence, Ohio  
April 19, 2009

Surgical techniques for epiretinal membrane removal

- Retinal Update for Ophthalmologists; Youngstown, Ohio  
March 18, 2009

Photodynamic therapy for central serous chorioretinopathy

- Cleveland Ophthalmological Society; Cleveland, Ohio  
February 10, 2009

Posterior complications of anterior segment surgery

- Optometric Retinal Update; Youngstown, Ohio  
September 18, 2008

Posterior complications of anterior segment surgery

- National Medical Association Annual Meeting; Atlanta, Georgia  
July 2008

Open forum presentation, Eye Care America; glaucoma screening booth

- Cleveland Medical Association-Radio One Health Fair  
April 27 & 28, 2008

Newest information on research and treatments for macular degeneration

- Macula Vision Research Foundation SupportSight Seminar, Middleburg Hts, Ohio  
April 8, 2008

Diabetic retinopathy

- Optometric Retinal Update; New Castle, Pennsylvania  
October 25, 2007

Update on management of macular edema

- Optometric Retinal Update; Youngstown, Ohio  
September 5, 2007

Rabb-Venable Fluorescein Angiography Conference

- National Medical Association Annual Meeting; Waikiki, Hawaii  
August 2007

Optic nerve head pits

- Cleveland Ophthalmological Society; Cleveland, Ohio  
April 10, 2007

Answers to the top 10 questions about macular degeneration

- Macula Vision Research Foundation SupportSight Seminar; Middleburg Hts, Ohio  
March 24, 2007

Complications of diabetic retinopathy

- First Annual Chairman's Research Forum, Diabetes Association of Greater Cleveland; Cleveland, Ohio  
Invited Speaker; November 2, 2006

Macular degeneration: causes, copings and cures

- Weils Community Event; Chagrin Falls, Ohio  
Invited Speaker; October 10, 2006

Grading diabetic retinopathy

- Optometric Retinal Update; Beachwood, Ohio  
September 28, 2006

Grading diabetic retinopathy

- Optometric Retinal Update; Youngstown, Ohio  
September 25, 2006

Ophthalmology and systemic diseases: utility of ophthalmologic input for diagnostic and therapeutic purposes

- Southwest Hospital Grand Rounds (CME credit course); Middleburg Hts, Ohio  
July 28, 2006

Clinical characteristics of complications in patients with 50 or more years of Type 1 diabetes

- National Medical Association 109<sup>th</sup> Annual Scientific Section; San Diego, California  
August 2004

Management of serous retinal detachments

- Aravind Eye Hospital, Department of Ophthalmology; Maduri, India  
June 2004

Clinical grading of diabetic retinopathy lecture series/conference

- Aravind Eye Hospital, Department of Ophthalmology; Maduri, India  
May 2004
- Massachusetts Eye & Ear Infirmary Resident Teaching; Boston, Massachusetts  
2003-2004

Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study

- Aravind Eye Hospital, Department of Ophthalmology; Maduri, India  
May 2004
- Case Western Reserve University Ninth Annual Resident and Alumni Research Day; Cleveland, Ohio  
June 2002

Optic nerve pits: the origin and management of serous retinal detachments

- Longwood Medical Association of Ophthalmology/Harvard Medical School; Boston, Massachusetts  
October 2003
- University Hospitals of Cleveland, Department of Ophthalmology, Grand Rounds  
Cleveland, Ohio  
June 2003

Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study;

- Aravind Eye Hospital, Department of Ophthalmology; Maduri, India  
May 2004
- American Society of Retina Specialists 21<sup>st</sup> Annual Meeting New York, New York  
August 2003
- National Medical Association 108<sup>th</sup> Annual Scientific Section; Philadelphia, Pennsylvania  
August 2003
- Case Western Reserve University Ninth Annual Resident and Alumni Research Day; Cleveland, Ohio  
June 2003

Angioid streaks: the management of CNVM

- Case Western Reserve University Second Annual Residents Day; Cleveland, Ohio  
March 2003

Current management of idiopathic parafoveal telangiectasis

- Case Western Reserve University Second Annual Residents Day; Cleveland, Ohio  
March 2003

Diagnosis & management of idiopathic polypoidal choroidopathy

- University Hospitals of Cleveland, Department of Ophthalmology, Grand Rounds; Cleveland, Ohio  
February 2003

Ocular manifestations of sarcoidosis

- Case Western Reserve University First Annual Residents Day; Cleveland, Ohio  
November 2001

## PUBLICATIONS

### *Journal Articles*

1. O'Grady MJ, Bressler NM, Glassman AR for the Diabetic Retinopathy Clinical Research Network. Economic analysis of ranibizumab treatment of diabetic macular edema. *JAMA* (submitted 2011).
2. Schartman JP, **Coney JM**, Miller DG. Pegaptanib octasodium for the treatment of diabetic macular oedema. *Expert Opinion on Pharmacotherapy* 2011;12:1317-1323.
3. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.. *N Engl J Med*. 2011 May 19;364:1897-1908. Epub 2011 Apr 28..
4. **Coney JM**, Schartman JP, Singerman LJ. Advancing treatments for diabetic macular edema. *Retinal Physician* 2011;8:40, 43-44, 46.
5. Diabetic Retinopathy Clinical Research Network; Writing Committee, Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2011;118:609-614.
6. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3rd, Gupta SK, Haller JA, Lazarus HS, Qin H. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research Network. *Retina* 2010;30:1488-1495.
7. **Coney JM**, Miller DG. Epiretinal membrane. *Focal Points*. Volume XXVII, Number 5, American Academy of Ophthalmology, 2009.
8. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
9. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.
10. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770-1777.

11. Patronas M, **Coney JM**, Singerman LJ. Treating neovascular peripheral retinal diseases. *Retinal Physician* 2008;5(8):53,54,56,58.
12. Coney JM, Novak MA, Zegarra H. New treatments for diabetic macular edema. *MD News* 2008; 12 (2):32, 34.
13. **Coney JM**, Singerman LJ. Patient management in intravitreal injections. *Retinal Physician* 2007;4:52,55.
14. Keenan HA, Costacou T, Doria A, **Coney JM**, Orchard TJ, Aiello LP, King GL. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the fifty-year medalist study. *Diabetes Care* 2007;30:1995-1997.
15. Jager RI, Timothy NH, **Coney JM**, Katalinic P, Cavicchi RW, Strong J, Cavallerano JD, Aiello LP. Congenital retinal macrovessel. *Retina, The Journal of Retinal and Vitreous Diseases* 2005;25:538-540.
16. Gurelik G, **Coney JM**, Zakov ZN. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study. *Ophthalmic Surg Lasers Imaging* 2004;35:94-102.
17. Kopstein A, **Coney J**, Bouchard CS. Corneal pachymetric and biomicroscopic changes after swimming with and without goggles: A prospective study. *Invest Ophthalmol Vis Sci* 1999;39:S913.

### **Posters**

1. Brown CC, Coney JM, H. Zegarra H. Results of photodynamic therapy with verteporfin for the treatment of central serous chorioretinopathy. Association for Research in Vision and Ophthalmology Annual Meeting. Program # 1341 / Poster #A354. Fort Lauderdale, Florida. May 3, 2010.
2. Clinical characteristics of complications in patients with 50 or more years of Type 1 diabetes; American Diabetes Association 64<sup>th</sup> Annual Scientific Section. Orlando, Florida; June 2004.
3. Evaluation of insulin dependent diabetic patients with more than fifty years of diabetes. Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida; April 2004.
4. Endophthalmitis as a complication of intravitreal injection: a systemic review. Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida; April 2004.
5. Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study. Association for Research in Vision and Ophthalmology Fort Lauderdale, Florida; May 2002

6. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study
  - Retina Society 36<sup>th</sup> Scientific Session; Chicago, Illinois; September 2003
  - Association for Research in Vision and Ophthalmology; Fort Lauderdale, Florida; May 2003
  
6. Measurement of corneal thickness changes after prolonged swimming with goggles. Association for Research in Vision and Ophthalmology; Fort Lauderdale, Florida; March 1999
  
7. I-CAM expression on bone marrow stromal cells
  - National Medical Research Forum; Galveston, Texas; April 1997
  - Student National Medical Association & National Institutes of Health; New Orleans, Louisiana; March 1997
  - Midwest Student Medical Research Forum; Omaha, Nebraska; February 1997
  - St. Luke's Research Forum, Loyola-Stritch School of Medicine; Maywood, Illinois; October 1996